Company:Glaukos
| File:Glaukos logo.png | |
| Type | Public |
|---|---|
| NYSE: GKOS | |
| Industry | Health care |
| Founded | 2001 |
| Founder |
|
| Headquarters | San Clemente, California , United States |
Key people | Thomas Burns (President and CEO) |
| Revenue |  US$45,600,000 (2014) |
 US$14,100,000 (loss) (2014) | |
| Footnotes / references financial information[1] | |
Glaukos Corporation is a glaucoma treatment company based in San Clemente, California.[1] Thomas Burns is Glaukos' president and CEO.[2]
Products
Glaukos developed the "iStent" titanium micro-stent. The device, which is about the width of a human hair, is implanted during cataract surgery to reduce intraocular pressure.[2] (As of 2015), the iStent was the smallest device ever approved by the United States Food and Drug Administration.[3] The availability of the iStent led to the addition of two codes to the Current Procedural Terminology set in 2015, 0191T and 0376T.[4]
Business model
In 2015, Glaukos planned to transition from private company status to become a public company with an initial public offering (IPO) of company stock.[1] The proposed stock symbol for the company was "GKOS".[1]
Glaukos' president and chief executive officer (CEO) Thomas Burns says Glaukos was the first to develop micro-stents for the treatment of glaucoma and is well ahead of its competitors.[2] The CEO of MicroOptx, Chris Pulling, has stated that Glaukos is his "most direct" competitor.[3]
History
Founded in 2001 by Olav Bergheim, Richard Hill and Mory Gharib, the company has raised $156 million in venture funding from Versant Ventures, OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Meritech Capital Partners, Domain Associates, Fjord Capital Management and Montreux Equity Partners.[2]
The company ranked 19th on the Wall Street Journal's annual Next Big Thing list in 2011.[2]
The company ranked seventh on the Wall Street Journal's annual Next Big Thing list in 2012.[2]
In June 2012, the Food and Drug Administration approved the first iStent implant.[2]
References
- ↑ 1.0 1.1 1.2 1.3 House, Douglas W. (19 June 2015). "Glaukos on deck for IPO". Seeking Alpha. http://seekingalpha.com/news/2591825-glaukos-on-deck-for-ipo.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Norman, Jan (27 September 2012). "O.C. glaucoma treatment firm Glaukos makes 'Next Big Thing' list". The Orange County Register. http://www.ocregister.com/articles/glaukos-372893-companies-capital.html. Retrieved 1 October 2012.
- ↑ 3.0 3.1 Grayson, Katharine (18 June 2015). "Startup with tiny glaucoma implant snags $2.4M". Minneapolis/St. Paul Business Journal. http://www.bizjournals.com/twincities/news/2015/06/18/microoptx-glaucoma-device-trials.html.
- ↑ Freeman, L. Neal (15 June 2015). "CPT coding for glaucoma surgery reporting undergoes changes". Ophthalmology Times (North Olmsted, Ohio: Medical Communications Group). http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/cpt-coding-glaucoma-surgery-reporting-undergoes-changes.
 |
